NEW YORK (GenomeWeb) – Cowen and JP Morgan both initiated coverage of Twist Bioscience today, citing the company's leadership role in the synthetic biology market and its ability to manufacture DNA cheaply and at scale using its commercial platform.

While Cowen assigned the company's shares a rating of Outperform, JP Morgan analyst Tycho Peterson gave them a more conservative rating of Neutral, saying in a note to investors that the stock's value has essentially doubled after the firm's initial public offering, prompting JP Morgan to wait for a more opportunistic entry point.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.